Cutting-Edge Technology and Mitochondrial Diseases - Where is the Limit?
By Dusko Ilic,
BioNews
| 07. 27. 2015
Untitled Document
In their latest study, published in the Nature, Shoukrat Mitalipov and collaborators, including Juan Carlos Izpisua Belmonte, reported on two potential 'gene correction' strategies that can help patients with mitochondrial diseases (1, BioNews 811). Both approaches are built on the idea of mitochondria segregation phenomenon, reported for the first time by a group from the Mayo clinic in Rochester, Minnesota(2).
Basically, in proliferating cells the mitochondria segregate spontaneously and, if we start with a heteroplasmic cell containing a mix of healthy, wild-type and mutation-carrying mitochondria, after multiple cell divisions daughter cells will segregate into three major groups. The first will contain predominantly healthy, wild-type mitochondria with a few-to-nil mitochondria that carry the mutation, while the second is quite opposite – a vast majority of mitochondria will be carrying the deleterious mutation and almost none will be healthy. The third group will be heteroplasmic, containing various degrees of mixed normal and mutation-carrying mitochondria.
Read more...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...